A national education program for pharmacists funded by the Australian Government under the Quality Use of Diagnostics, Therapeutics and Pathology program.[/caption]
While the evidence bases for both CMs and Schedule 3 sleep aids are unlikely to immediately change, a core practice consideration is the risk-benefit profile of the respective non-prescription sleep aids for the individual patient. 
Is it really insomnia?
Knowledge to practice 
Pregabalin add-on for drug-resistant focal epilepsy
This evidence summary presents the best available evidence regarding pregabalin add-on for drug-resistant focal epilepsy.1
Introduction
Approximately 3–3.5% of Australians will experience epilepsy at some point...
Marea O’Donnell extended interview
As a pharmacist who cares about people, any extra involvement of having pharmacists in aged care is going to be good. It’s going to...
Is Australia’s scope of care lagging behind?
Nations around the globe used to look to Australia for examples of bold and innovative pharmacy funding projects. But many of our overseas peers...
Pharmacists in 2023: Unlocking the opportunity
It’s time for PSA to reveal our vision of the future of pharmacy in Australia.
I am pleased to announce our Pharmacists in 2023...
Minor Ailments Scheme gets 10/10 from Scottish patients
A new report indicates the ‘undeniable popularity’ of Scotland’s Minor Ailment Scheme (MAS), as support swells amongst pharmacy groups for its implementation in Australia....
Digital transformation with My Health Record
Pharmacists should be actively contributing to patients' My Health Record (MHR) in order to unlock the full potential of digital transformation, said Dr Kenneth...
